These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31324691)

  • 41. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
    Wang Z; Turner R; Baker BM; Biddison WE
    J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural patterns in class 1 major histocompatibility complex-restricted nonamer peptide binding to T-cell receptors.
    T RR; Smith JC
    Proteins; 2022 Sep; 90(9):1645-1654. PubMed ID: 35403257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MPID-T: database for sequence-structure-function information on T-cell receptor/peptide/MHC interactions.
    Tong JC; Kong L; Tan TW; Ranganathan S
    Appl Bioinformatics; 2006; 5(2):111-4. PubMed ID: 16722775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP.
    Lewis JW; Neisig A; Neefjes J; Elliott T
    Curr Biol; 1996 Jul; 6(7):873-83. PubMed ID: 8805302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased efficiency of folding and peptide loading of mutant MHC class I molecules.
    Beissbarth T; Sun J; Kavathas PB; Ortmann B
    Eur J Immunol; 2000 Apr; 30(4):1203-13. PubMed ID: 10760810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
    Blaha DT; Anderson SD; Yoakum DM; Hager MV; Zha Y; Gajewski TF; Kranz DM
    Cancer Immunol Res; 2019 Jan; 7(1):50-61. PubMed ID: 30425106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human TCR-binding affinity is governed by MHC class restriction.
    Cole DK; Pumphrey NJ; Boulter JM; Sami M; Bell JI; Gostick E; Price DA; Gao GF; Sewell AK; Jakobsen BK
    J Immunol; 2007 May; 178(9):5727-34. PubMed ID: 17442956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide.
    Vessey SJ; Barouch DH; McAdam SN; Tussey LG; Davenport MA; O'Callaghan CA; Bell JI; McMichael AJ; Jakobsen BK
    Eur J Immunol; 1997 Apr; 27(4):879-85. PubMed ID: 9130639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MHC Molecules, T cell Receptors, Natural Killer Cell Receptors, and Viral Immunoevasins-Key Elements of Adaptive and Innate Immunity.
    Jiang J; Natarajan K; Margulies DH
    Adv Exp Med Biol; 2019; 1172():21-62. PubMed ID: 31628650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flexibility in T-cell receptor ligand repertoires depends on MHC and T-cell receptor clonotype.
    Geluk A; van Meijgaarden KE; Ottenhoff TH
    Immunology; 1997 Mar; 90(3):370-5. PubMed ID: 9155643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM.
    Saotome K; Dudgeon D; Colotti K; Moore MJ; Jones J; Zhou Y; Rafique A; Yancopoulos GD; Murphy AJ; Lin JC; Olson WC; Franklin MC
    Nat Commun; 2023 Apr; 14(1):2401. PubMed ID: 37100770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low affinity interaction of peptide-MHC complexes with T cell receptors.
    Matsui K; Boniface JJ; Reay PA; Schild H; Fazekas de St Groth B; Davis MM
    Science; 1991 Dec; 254(5039):1788-91. PubMed ID: 1763329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
    Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
    J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MM-GBSA binding free energy decomposition and T cell receptor engineering.
    Zoete V; Irving MB; Michielin O
    J Mol Recognit; 2010; 23(2):142-52. PubMed ID: 20151417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conserved Vδ1 Binding Geometry in a Setting of Locus-Disparate pHLA Recognition by δ/αβ T Cell Receptors (TCRs): Insight into Recognition of HIV Peptides by TCRs.
    Shi Y; Kawana-Tachikawa A; Gao F; Qi J; Liu C; Gao J; Cheng H; Ueno T; Iwamoto A; Gao GF
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
    Lev A; Novak H; Segal D; Reiter Y
    J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.